急性髓系白血病初始治疗的个体化：将新型药物纳入临床实践。
Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.
作者信息
DeStefano Christin B, Hourigan Christopher S
机构信息
Laboratory of Myeloid Malignancies, National Institutes of Health, Bethesda, MD, USA Department of Hematology, MedStar Washington Cancer Institute, Washington, DC, USA.
Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10-CRC, Room 5-5130, 10 Center Drive, Bethesda, MD 20814-1476, USA.
出版信息
Ther Adv Hematol. 2018 May;9(5):109-121. doi: 10.1177/2040620718761778. Epub 2018 Mar 27.
While the past decade has seen a revolution in understanding of the genetic and molecular etiology of the disease, in clinical practice, initial therapy for acute myeloid leukemia (AML) patients has been a relatively straightforward choice between intensive combination cytotoxic induction therapy as used for decades or less-intensive hypomethylating therapy. The year 2017, however, witnessed US Food and Drug Administration approvals of midostaurin, enasidenib, gemtuzumab ozogamicin and CPX-351 for AML patients, with many other promising agents currently in clinical trials. This review discusses these options, highlights unanswered questions regarding optimal combinations and proposes some suggested approaches for the personalization of initial therapy for AML patients.
在过去十年里，人们对该疾病的遗传和分子病因的理解有了革命性进展，但在临床实践中，急性髓系白血病（AML）患者的初始治疗一直是在沿用数十年的强化联合细胞毒性诱导疗法和强度较低的去甲基化疗法之间进行相对简单的选择。然而，2017年美国食品药品监督管理局批准了米哚妥林、恩杂鲁胺、吉妥珠单抗奥唑米星和CPX-351用于AML患者，目前还有许多其他有前景的药物正在进行临床试验。本文综述了这些选择，强调了关于最佳联合用药尚未解决的问题，并提出了一些AML患者初始治疗个性化的建议方法。
Zotero 插件